Reviewing therapy with radioisotopes for pain bone metastasis and its possible evolution

Authors

  • Daniel Coiro Silva Santa Casa Bahia
  • Roberto Jose Meyer Nascimento

DOI:

https://doi.org/10.15392/bjrs.v10i2.2011

Keywords:

Radiopharmaceuticals. Radioisotope. Metastasis. Bone

Abstract

Introduction: The therapy with radioisotopes is widely used, its beginnings were focused on thyroid pathologies treatments.  Over the years, the radiopharmaceuticals and/or radioisotopes have had their usage increased, to be used on painful bone metastasis. Material and Methods: A bibliographic search was conducted in the major health Science basis to evaluate what the therapies have to offer for patients in this condition. Results: Currently there are only two available materials in Brazil, the Sm153 that is national production, and Ra223, that is imported. Outside Brazil we can find a variety of materials that have already been approved by the Sanitary Organization in other countries, even though we are not authorized to use them due to Brazilian Regulation and production issues. Conclusion: Besides the diversity of materials that could be used, dosimetry systems must be implemented in order to have a more efficient treatment and to have an accurate administrated activities to patients.

 

Downloads

Download data is not yet available.

References

V. Ralph McCready. Radioiodine – the success story of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2017) 44:179–182 DOI: https://doi.org/10.1007/s00259-016-3548-5

Luis Costa & Xavier Badia & Edward Chow et all. Impact of skeletal complications on patients’ quality of life, mobility, and functional Independence. Support Care Cancer (2008) 16:879–889 DOI: https://doi.org/10.1007/s00520-008-0418-0

Narendra Nair, Relative Efficacy of 32P and 89Sr in Palliation in Skeletal Metastases. J NucI Med1999.40:256 a 261

Neeta Pandit-Taskar, Steven M. Larson et all, Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: Therapy with 223Ra-Dichloride. J Nucl Med 2014; 55:268–274 DOI: https://doi.org/10.2967/jnumed.112.112482

Hélène Kolesnikov-Gauthier, Nathalie Lemoine, Emmanuelle Tresch-Bruneel et all. Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study. Support Care Cancer DOI 10.1007/s00520-017-3885-3.

Ajit S. Shinto, Madhava B. Mallia, Mythili Kameswaran, et all. Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. World J Nucl Med. 2018 Oct-Dec; 17(4): 228–235. DOI: https://doi.org/10.4103/wjnm.WJNM_68_17

Jörgen Elgqvist,SofiaFrost, Jean-Pierre Pouget,PerAlbertsson. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Frontiers in Oncology January 2014 | Volume 3 | Article 324 DOI: https://doi.org/10.3389/fonc.2013.00324

Mareike Roscher , Gábor Bakos and Martina Benešová. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 2020, 13, 76.

G.B. Saha, Fundamentals of Nuclear Pharmacy, Springer International Publishing AG 2018 (paperback). DOI: https://doi.org/10.1007/978-3-319-57580-3

Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br J Radiol 2018; 91 DOI: https://doi.org/10.1259/bjr.20170969

Maria E. Lyra, Maria Andreou, Antonios Georgantzoglou et all. Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry. Current Medical Imaging Reviews, 2013, 9, 51-75 51. DOI: https://doi.org/10.2174/1573405611309010008

Hojjat Ahmadzadehfar, MD, MSc , Markus Essler, MD , Kambiz Rahbar, MD , et all Radionuclide Therapy for bone metastases utility of scintigraphy and PET imaging for treatment planning. PET Clin. 2018; 13:491–503). DOI: https://doi.org/10.1016/j.cpet.2018.05.005

Joon Young Choi. Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals. Nuclear Medicine and Molecular Imaging (2018) 52:200–207 DOI: https://doi.org/10.1007/s13139-017-0509-2

George Sgouros , Lisa Bodei , Michael R. McDevitt et all. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19, 819 (2020) DOI: https://doi.org/10.1038/s41573-020-0085-5

Mareike Roscher, Gábor Bakos, Martina Benešová. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 020, 13, 76; DOI: https://doi.org/10.3390/ph13040076

Stephen A. Graves, PhD, and Robert F. Hobbs, PhD. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Semin Radiat Oncol 31:37−44.2020 DOI: https://doi.org/10.1016/j.semradonc.2020.07.008

Ashutosh Dash, Tapas Das, and Furn F. (Russ) Knapp Jr. Targeted Radionuclide Therapy of Painful Bone Metastases: Past De- velopments, Current Status, Recent Advances and Future Directions. Current Medicinal Chemistry, 2020, 27, 3187-3249 DOI: https://doi.org/10.2174/0929867326666190201142814

Diretrizes básicas de proteção radiológica. Norma CNENNN3.01 Resolução 164/14Março/2014

Requisitos de segurança e proteção radiológica para serviços de medicina nuclear. Norma CNEN NN 3.05 Resolução CNEN 159/13 dez./2013

Resolução-RDC No 64, de 18 de dezembro de 2009. ANVISA

Downloads

Published

2022-06-13

How to Cite

Coiro Silva, D., & Jose Meyer Nascimento, R. (2022). Reviewing therapy with radioisotopes for pain bone metastasis and its possible evolution. Brazilian Journal of Radiation Sciences, 10(2). https://doi.org/10.15392/bjrs.v10i2.2011

Issue

Section

Review Articles